Quad Chemo for Bladder Cancer Treatment
Author Information
Author(s): McElree Ian M., Packiam Vignesh T., Steinberg Ryan L., Hougen Helen Y., Abou Chakra Mohamad, Mott Sarah L., O’Donnell Michael A.
Primary Institution: University of Iowa
Hypothesis
Can a sequential chemotherapy regimen improve outcomes for patients with recurrent non-muscle invasive urothelial carcinoma?
Conclusion
Quad Chemo treatment resulted in significant disease-free rates at 3 months and 2 years, but disease progression remains a concern.
Supporting Evidence
- 80% of treated units were disease-free at 3 months.
- 43% of treated units were disease-free at 2 years.
- 10 patients experienced disease progression, yielding a 5-year progression-free survival of 57%.
- 66% of patients reported side effects during treatment.
Takeaway
This study tested a new treatment for bladder cancer that combines several drugs, and it helped many patients stay cancer-free for a while, but some still had their cancer come back later.
Methodology
Patients received a regimen of doxorubicin and gemcitabine alternating weekly with docetaxel and mitomycin over 8 weeks, followed by maintenance treatments if disease-free.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study's retrospective design may introduce selection bias and limit generalizability; small sample size and single-institution data may not reflect broader patient populations.
Participant Demographics
The cohort included 29 patients, predominantly male (90%), with a median age of 77 years.
Statistical Information
Confidence Interval
43-74%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website